198 related articles for article (PubMed ID: 35249925)
21. [Immune-Related Pancreatitis Caused by Immune Checkpoint Inhibitor Nivolumab:Report of One Case].
Xu F; Shen Z; Tao H; Zhu Z; Tao JL; Feng ZY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Apr; 45(2):351-354. PubMed ID: 37157088
[TBL] [Abstract][Full Text] [Related]
22. Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.
Ando T; Ueda A; Ogawa K; Motoo I; Kajiura S; Nakajima T; Hirano K; Okumura T; Tsukada K; Hara T; Suzuki N; Nakada N; Horikawa N; Fujii T; Yasuda I
In Vivo; 2021; 35(1):475-482. PubMed ID: 33402499
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
Vicino A; Hottinger AF; Latifyan S; Boughdad S; Becce F; Prior JO; Kuntzer T; Brouland JP; Dunet V; Obeid M; Théaudin M
J Neurol; 2024 Apr; 271(4):1947-1958. PubMed ID: 38141128
[TBL] [Abstract][Full Text] [Related]
24. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.
Darnell EP; Mooradian MJ; Baruch EN; Yilmaz M; Reynolds KL
Curr Oncol Rep; 2020 Mar; 22(4):39. PubMed ID: 32200442
[TBL] [Abstract][Full Text] [Related]
25. New biomarker-based strategy screens for myocarditis after immune checkpoint inhibitor treatment.
Nierengarten MB
Cancer; 2023 May; 129(9):1304. PubMed ID: 37029508
[No Abstract] [Full Text] [Related]
26. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma.
Chen Q; Huang DS; Zhang LW; Li YQ; Wang HW; Liu HB
Clin Toxicol (Phila); 2018 Jul; 56(7):667-671. PubMed ID: 29126352
[TBL] [Abstract][Full Text] [Related]
27. [Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC): a case report].
Tan KX; Li CY; Zhang JY; Cui HJ; Shen W; Zhang X; Sun CY; Jiang XJ; Zheng SY; Li J; Xue CX
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1047-1048. PubMed ID: 33342162
[No Abstract] [Full Text] [Related]
28. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Mahmood SS; Fradley MG; Cohen JV; Nohria A; Reynolds KL; Heinzerling LM; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Awadalla M; Hassan MZO; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Lawrence DP; Groarke JD; Neilan TG
J Am Coll Cardiol; 2018 Apr; 71(16):1755-1764. PubMed ID: 29567210
[TBL] [Abstract][Full Text] [Related]
29. Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer.
Takada S; Murooka H; Tahatsu K; Yanase M; Umehara K; Hashishita H; Toru H; Satoru M; Sagawa T; Fujikawa K; Sato H; Mino K
Asian Pac J Cancer Prev; 2022 Feb; 23(2):695-701. PubMed ID: 35225483
[TBL] [Abstract][Full Text] [Related]
30. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
31. Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data.
Fan Q; Hu Y; Yang C; Zhao B
Int Immunopharmacol; 2019 Nov; 76():105866. PubMed ID: 31491729
[TBL] [Abstract][Full Text] [Related]
32. Profound postinduction hypotension precipitated by immune checkpoint inhibitors: a case report.
Che L; Zhu A; Chen W; Yu C
J Med Case Rep; 2024 Mar; 18(1):146. PubMed ID: 38459576
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.
Raschi E; Rossi S; De Giglio A; Fusaroli M; Burgazzi F; Rinaldi R; Potena L
Drug Saf; 2023 Sep; 46(9):819-833. PubMed ID: 37341925
[TBL] [Abstract][Full Text] [Related]
34. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
35. Sinus Node Dysfunction Co-occurring with Immune Checkpoint Inhibitor-associated Myocarditis.
Nishikawa T; Kunimasa K; Ohta-Ogo K; Ikeda Y; Yasui T; Shioyama W; Oka T; Honma K; Hatakeyama K; Kumagai T; Fujita M
Intern Med; 2022 Jul; 61(14):2161-2165. PubMed ID: 35283377
[TBL] [Abstract][Full Text] [Related]
36. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis.
Li MT; He Y; Huang SY; Hu X; Chen JS
Invest New Drugs; 2024 Feb; 42(1):116-126. PubMed ID: 38253746
[TBL] [Abstract][Full Text] [Related]
38. Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.
Vasbinder A; Ismail A; Salem JE; Hayek SS
Curr Cardiol Rep; 2023 Sep; 25(9):959-967. PubMed ID: 37436648
[TBL] [Abstract][Full Text] [Related]
39. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series.
Coustal C; Vanoverschelde J; Quantin X; Lesage C; Michot JM; Lappara A; Ederhy S; Assenat E; Faure M; Issa N; Lambotte O; Puyade M; Dereure O; Tosi D; Rullier P; Serre I; Larcher R; Klouche K; Chanques G; Vernhet-Kovacsik H; Faillie JL; Agullo A; Roubille F; Guilpain P; Maria ATJ
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258037
[TBL] [Abstract][Full Text] [Related]
40. Severe multiple simultaneous immune-related adverse events in a patient with head and neck cancer.
Aoki K; Hamamoto T; Chikuie N; Kono T; Taruya T; Ishino T; Ueda T; Takeno S
Auris Nasus Larynx; 2023 Apr; 50(2):309-313. PubMed ID: 35181217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]